Susceptibility, tumor progression and resistance
Pujana’s Lab

DESCRIPTION

Targeting cancer complexity at origin and progression

Our research is focused on better understanding breast cancer initiation and, from acquired knowledge, to assess targeted prevention strategies. In parallel, we study pan-cancer vulnerabilities and the connection to a rare, lung metastatic disease, lymphangioleiomyomatosis (LAM).

Group members

Miquel Angel Pujana

Group leaders

Principal investigator

Francesca Mateo

Researchers

Research assistant

Roderic Espín

Young investigators

PhD student

Lara Ruiz

Young investigators

PhD student

Arzoo Shabbir

Young investigators

PhD student

Luís Alfaro

Young investigators

PhD student

Publications

Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy

13 de January de 2022/in Pujana's Lab/by miguel

Clin Cancer Res. 2022 Apr 1;28(7):1372-1382. doi: 10.1158/1078-0432.CCR-21-2846. ABSTRACT PURPOSE: Loss of TGFβ signaling increases error-prone alternative end-joining (alt-EJ) DNA repair. We previously translated this mechanistic relationship as TGFβ and alt-EJ gene expression signatures, which we showed are anticorrelated across cancer types. A score representing anticorrelation, βAlt, predicts patient outcome in response to genotoxic therapy. […]

Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion

4 de November de 2021/in Pujana's Lab/by miguel

Nature. 2021 Nov;599(7886):673-678. doi: 10.1038/s41586-021-04057-2. Epub 2021 Nov 3. ABSTRACT Immune exclusion predicts poor patient outcomes in multiple malignancies, including triple-negative breast cancer (TNBC)1. The extracellular matrix (ECM) contributes to immune exclusion2. However, strategies to reduce ECM abundance are largely ineffective or generate undesired outcomes3,4. Here we show that discoidin domain receptor 1 (DDR1), a […]

Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants

22 de August de 2021/in Pujana's Lab/by miguel

Hum Mutat. 2021 Nov;42(11):1488-1502. doi: 10.1002/humu.24276. Epub 2021 Aug 31. ABSTRACT Germline pathogenic variants in BRCA1 confer a high risk of developing breast and ovarian cancer. The BRCA1 exon 11 (formally exon 10) is one of the largest exons and codes for the nuclear localization signals of the corresponding gene product. This exon can be […]

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

28 de July de 2021/in Pujana's Lab/by miguel

J Natl Cancer Inst. 2022 Jan 11;114(1):109-122. doi: 10.1093/jnci/djab147. ABSTRACT BACKGROUND: Recent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers. METHODS: 483 BRCA1 and 1318 BRCA2 European ancestry […]

Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue

27 de July de 2021/in Pujana's Lab/by miguel

Mol Cancer Res. 2021 Nov;19(11):1840-1853. doi: 10.1158/1541-7786.MCR-21-0220. Epub 2021 Jul 26. ABSTRACT Lymphangioleiomyomatosis (LAM) is a rare, low-grade metastasizing disease characterized by cystic lung destruction. LAM can exhibit extensive heterogeneity at the molecular, cellular, and tissue levels. However, the molecular similarities and differences among LAM cells and tissue, and their connection to cancer features are […]

Research Projects

The group works and collaborates to decipher the systems mechanisms of cancer development and progression, with the aim of developing more precise preventive and therapeutic approaches. The group combines in silico and wet-lab studies for the purpose of identifying cancer principles and vulnerabilities.

Collaborations

CIMBA – Consortium of Investigators of Modifiers of BRCA1/2

https://cimba.ccge.medschl.cam.ac.uk/

Lobular Breast Cancer

https://lobsterpot.eu/

BRCA1 breast cancer

Khokha Lab

https://medbio.utoronto.ca/faculty/khokha

Hakem Lab

https://medbio.utoronto.ca/faculty/hakem

Maxwell Lab

https://www.bcchr.ca/cmaxwell

Serra Lab

https://vhio.net/biosketch-violeta-serra/

Cancer biology

Schramek Lab

https://schramek.lunenfeld.ca/

Li Lab

https://lilab.smhs.gwu.edu/

Barcellos-Hoff Lab

https://barcelloshofflab.ucsf.edu/principal-investigator

Cancer genetics

De Cid Lab – GCAT

http://www.gcatbiobank.org/

LAM research

Johnson Lab – LAM UK

https://www.nottingham.ac.uk/medicine/people/simon.johnson

Elżbieta Radzikowska

National Tuberculosis and Lung Diseases Research Institute, Poland

Kwiatkowski Lab

https://www.kwiatkowskilab.org/

AELAM

https://www.aelam.org/

VHIR

https://vhir.vallhebron.com/en/research/pneumology

Molina Lab

https://idibell.cat/en/research/translational-medicine-area/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program/pneumology/

Susceptibility, tumor progression and resistancePujana’s Lab

DESCRIPTION

Miquel Angel Pujana

Group leaders

Francesca Mateo

Researchers

Roderic Espín

Young investigators

Lara Ruiz

Young investigators

Arzoo Shabbir

Young investigators

Luís Alfaro

Young investigators

CONTACT US

Susceptibility, tumor progression and resistance
Pujana’s Lab